UC Berkeley researchers say large language models have gained "metalinguistic ability," a hallmark of human language and ...

With capital drying up and market tailwinds gone, the biotech industry — including Recursion — needs to make tactical decisions.

Recursion Pharmaceuticals (RXRX) stock gains as the company plans a 20% workforce reduction to streamline operations and extend cash runway to Q4 2027. Read more here.

Recursion Pharmaceuticals said on Tuesday it would lay off about 20% of its workforce as the biotech company tries to cope with an industry-wide funding crunch and the current policy uncertainty.

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading higher and trending. The company on Tuesday announced a reduction in personnel and infrastructure aimed at extending its cash runway.

Recursion Pharmaceuticals is laying off a fifth of its workforce in connect with a previously announced streamlining of the AI biotech’s pipeline.

Recursion Pharmaceuticals will lay off roughly 20% of its workforce, affecting some 160 employees, in a bid to extend its cash runway. In an SEC filing on Tuesday, the Utah-based biotech announced ...

This repository presents the formal attribution, protected expression, and public overview of: Ξ (ψ) = ψᴽ + Γ (ψ)The symbolic recursion engine powering Quantum Observer Field Theory (QOFT) This ...

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...

AI business Recursion Pharmaceuticals has narrowed its drug development pipeline, ending or pausing five programmes as it seeks to reduce costs and reprioritise resources following a merger with ...